title: Pharmacological and behavioral characterization of the saphenous chronic constriction injury model of neuropathic pain in rats.
abstract: The aim of the present study was to develop a new experimental pain model by adapting the chronic constriction injury (CCI) model of the sciatic nerve to the exclusively sensory saphenous nerve in rats. Animals were divided into naïve, sham, and two experimental groups, in which two or four 4-0 chromic gut ligatures were loosely ligated around the saphenous nerve. Then, behavioral signs of neuropathic pain were observed for 8 weeks. In rats with four ligatures, prominent mechanical allodynia and thermal hyperalgesia developed; these behavioral signs were not prominent in rats with two ligatures. Pharmacological analysis was made in rats with four loose ligations; morphine and WIN 55,212-2, a cannabinoid agonist, reversed all of the modalities tested, whereas gabapentin only suppressed mechanical allodynia and amitriptyline only reduced mechanical hyperalgesia. Our data establish a rat model of saphenous CCI with significant allodynia and hyperalgesia, which is sensitive to a number of analgesic compounds.
authors: Department of Pharmacology, Faculty of Medicine, Trakya University, 22030 Edirne, Turkey.
authors: Ozgur
authors: O
authors: Gunduz
authors: Cagatay
authors: C
authors: Oltulu
authors: Rabia
authors: R
authors: Guven
authors: Dilek
authors: D
authors: Buldum
authors: Ahmet
authors: A
authors: Ulugol
mesh_terms: D000588:Amines / Q000494:pharmacology / Q000627:therapeutic use; D000639:Amitriptyline / Q000494:pharmacology / Q000627:therapeutic use; D000700:Analgesics / Q000494:pharmacology / Q000627:therapeutic use*; D000818:Animals; D048588:Benzoxazines / Q000494:pharmacology / Q000627:therapeutic use; D002908:Chronic Disease; D003250:Constriction; D003509:Cyclohexanecarboxylic Acids / Q000494:pharmacology / Q000627:therapeutic use; D004195:Disease Models, Animal; D000077206:Gabapentin; D006930:Hyperalgesia / Q000145:classification / Q000188:drug therapy / Q000209:etiology; D008026:Ligation / Q000379:methods; D008297:Male; D009020:Morphine / Q000627:therapeutic use; D009025:Morpholines / Q000494:pharmacology / Q000627:therapeutic use; D009281:Naphthalenes / Q000494:pharmacology / Q000627:therapeutic use; D009437:Neuralgia / Q000188:drug therapy* / Q000209:etiology / Q000503:physiopathology*; D010147:Pain Measurement; D017288:Pain Threshold / Q000187:drug effects*; D010812:Physical Stimulation / Q000009:adverse effects; D051381:Rats; D017208:Rats, Wistar; D013997:Time Factors; D005680:gamma-Aminobutyric Acid / Q000494:pharmacology / Q000627:therapeutic use
chemical_list: D000588:Amines; D000700:Analgesics; D048588:Benzoxazines; D003509:Cyclohexanecarboxylic Acids; D009025:Morpholines; D009281:Naphthalenes; D000639:Amitriptyline; D005680:gamma-Aminobutyric Acid; C070417:(3R)-((2,3-dihydro-5-methyl-3-((4-morpholinyl)methyl)pyrrolo-(1,2,3-de)-1,4-benzoxazin-6-yl)(1-naphthalenyl))methanone; D000077206:Gabapentin; D009020:Morphine